Circovac
adjuvanted inactivated vaccine against porcine circovirus type 2
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Circovac. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Circovac.
For practical information about using Circovac, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Circovac
|
Agency product number |
EMEA/V/C/000114
|
Active substance |
inactivated porcine circovirus type 2 (PCV2)
|
International non-proprietary name (INN) or common name |
adjuvanted inactivated vaccine against porcine circovirus type 2
|
Species |
Pigs (gilts and sows)
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AA07
|
Publication details | |
---|---|
Marketing-authorisation holder |
CEVA-Phylaxia Oltóanyagtermelõ Zrt.
|
Revision |
12
|
Date of issue of marketing authorisation valid throughout the European Union |
21/06/2007
|
Contact address |
Szállás u. 5.
1107 Budapest Hungary |
Product information
09/09/2021 Circovac - EMEA/V/C/000114 - WS1945/0018
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for suidae
Therapeutic indication
Sows and gilts
Passive immunisation of piglets via the colostrum, after active immunisation of sows and gilts, to reduce lesions in lymphoid tissues associated with PCV2 infection and as an aid to reduce PCV2-linked mortality.
Piglets
Active immunisation of piglets to reduce faecal excretion of PCV2 and virus load in blood, and as an aid to reduce PCV2-linked clinical signs, including wasting, weight loss and mortality, as well as to reduce virus load and lesions in lymphoid tissues associated with PCV2 infection.